Hematologic Oncology

December 7, 2020 - The addition of subcutaneous daratumumab to pomalidomide and dexamethasone significantly reduced the risk of progression or death by 37%, compared with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma who had received ≥1 prior line of therapy.

December 6, 2020 - Self-reported black race was found to be the most important factor associated with poor survival in patients under 60 years old with acute myeloid leukemia.

Treatment with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel was found to yield clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma.

CC-92480, a novel oral cereblon E3 ligase modulator agent, plus dexamethasone demonstrated immunomodulatory activity across all dose levels examined in patients with relapsed/refractory multiple myeloma, according to data from the first portion of the ongoing phase 1 CC-92480-MM-001 trial presented during the 2020 ASH Annual Meeting & Exposition.

December 6, 2020 - Odronextamab, is a novel CD20xCD3 bispecific antibody, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

December 6, 2020 - Orca-T, a precision Treg-engineered donor product, demonstrated preventive potential for graft-versus-host disease, with less immunosuppression, compared with the standard of care in patients with high-risk hematologic malignancies who underwent hematopoietic stem cell transplantation.

Corey S. Cutler, MD, MPH, FRCPC, discusses ​the results of the ROCKstar study in chronic graft-versus-host disease.

Ciltacabtagene autoleucel was found to elicit clinically meaningful improvements in health-related quality of life in patients with relapsed/refractory multiple myeloma, and this benefit may become even more pronounced as responses to treatment deepen over time, according to data from the CARTITUDE-1 study presented during the 2020 ASH Annual Meeting & Exposition.

December 6, 2020 - The bispecific IgM antibody IGM-2323 shrank tumors in 9 of 14 patients with CD20-positive, relapsed/refractory non-Hodgkin lymphomas in preliminary results from a phase 1 clinical trial presented at the 2020 ASH Annual Meeting

Sabatolimab demonstrated comparable pharmacokinetic activity at doses of 200 mg every 2 weeks and 800 mg every 4 weeks in combination with hypomethylating agents in patients with acute myeloid leukemia and myelodysplastic syndrome.

December 6, 2020 - The first-of-its-kind FcRH5xCD3 bispecific antibody cevostamab demonstrated a manageable safety profile with an overall response rate of 53% in heavily pretreated patients with relapsed/refractory multiple myeloma who received active doses.

December 6, 2020 — TTI-622, an investigational CD47 inhibitor, showed preliminary signs of clinical activity with a manageable safety profile among patients with relapsed/refractory lymphoma.

December 6, 2020 — The investigational TKI asciminib was found to be a safe and effective treatment for patients with chronic myeloid leukemia without any alternatives in clinical practice, particularly those with prior TKI intolerance and those who achieved prior complete cytogenetic response.

December 6, 2020 — Patients with hematologic malignancies are at increased risk for significant morbidity and mortality from coronavirus disease 2019, and the risk of death appeared to be greatest in those who were older, had more severe infection, a poorer prognosis, or who decided to forego intensive treatment

December 6, 2020 - UCART22, an allogeneic off-the-shelf CD22-directed T-cell product, showed no unexpected toxicities at 2 dose levels and had early signs of activity in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

December 6, 2020 - Having a human leukocyte antigen–matching donor for allogeneic hematopoietic stem cell transplant has proven to lead to improved outcomes for patients who are between 50 and 75 years of age and have higher-risk myelodysplastic syndrome.

December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.

Oral azacitidine demonstrated sustained health-related quality of life compared with placebo in patients with acute myeloid leukemia, according to results of the phase 3 QUAZAR AML-001 trial.

A novel combination comprised of the oral, selective RARα agonist SY-1425 and azacitidine demonstrated clinical activity with acceptable tolerability in a heavily pretreated population of patients with relapsed/refractory acute myeloid leukemia with RARA positivity.

The anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 showed clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

December 5, 2020 - Patients with heavily pretreated multiple myeloma maintained durable responses with the chimeric antigen receptor T-cell therapy idecabtagene vicleucel in updated findings presented from the phase 1 CRB-401 trial.

William G. Wierda, MD, PhD, discusses results from the CAPTIVATE trial in chronic lymphocytic leukemia and small lymphocytic lymphoma.

December 5, 2020 - Patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax and rituximab had a sustained progression-free survival and overall survival benefit at five years compared with those treated with bendamustine and rituximab.

December 5, 2020 - Axicabtagene ciloleucel demonstrated high rates of durable responses in patients with indolent non-Hodgkin lymphoma.

December 5, 2020 - Patients with previously untreated chronic lymphocytic leukemia /small lymphocytic lymphoma who received a placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease.